Taysha Gene Therapies (TSHA) Competitors

$5.96 0.00 (0.00%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$6.11 +0.15 (+2.58%)

As of 06:36 AM Eastern

TSHA vs. HHH, PCVX, KYMR, QGEN, and TGTX

Should you buy Taysha Gene Therapies stock or one of its competitors? MarketBeat compares Taysha Gene Therapies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Taysha Gene Therapies include Howard Hughes (HHH), Vaxcyte (PCVX), Kymera Therapeutics (KYMR), Qiagen (QGEN), and TG Therapeutics (TGTX).

How does Taysha Gene Therapies compare to Howard Hughes?

Howard Hughes (NYSE:HHH) and Taysha Gene Therapies (NASDAQ:TSHA) are related companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

93.8% of Howard Hughes shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 48.0% of Howard Hughes shares are owned by insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Taysha Gene Therapies had 3 more articles in the media than Howard Hughes. MarketBeat recorded 4 mentions for Taysha Gene Therapies and 1 mentions for Howard Hughes. Howard Hughes' average media sentiment score of 0.81 beat Taysha Gene Therapies' score of 0.69 indicating that Howard Hughes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Howard Hughes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Howard Hughes	$1.47B	2.58	$131.88M	$2.04	31.30
Taysha Gene Therapies	$9.77M	175.30	-$109M	-$0.38	N/A

Howard Hughes presently has a consensus price target of $85.00, indicating a potential upside of 33.11%. Taysha Gene Therapies has a consensus price target of $11.64, indicating a potential upside of 95.24%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Howard Hughes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Howard Hughes	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Howard Hughes has a net margin of 8.04% compared to Taysha Gene Therapies' net margin of 0.00%. Howard Hughes' return on equity of 5.41% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Howard Hughes	8.04%	5.41%	1.61%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Howard Hughes has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Summary

Howard Hughes beats Taysha Gene Therapies on 10 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Vaxcyte had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 5 mentions for Vaxcyte and 4 mentions for Taysha Gene Therapies. Vaxcyte's average media sentiment score of 0.85 beat Taysha Gene Therapies' score of 0.69 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies has higher revenue and earnings than Vaxcyte. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Taysha Gene Therapies	$9.77M	175.30	-$109M	-$0.38	N/A

Vaxcyte has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Vaxcyte's return on equity of -32.51% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Vaxcyte presently has a consensus price target of $86.00, indicating a potential upside of 64.15%. Taysha Gene Therapies has a consensus price target of $11.64, indicating a potential upside of 95.24%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Taysha Gene Therapies beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

77.7% of Taysha Gene Therapies shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Kymera Therapeutics had 7 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 11 mentions for Kymera Therapeutics and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.69 beat Kymera Therapeutics' score of 0.30 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	172.47	-$311.35M	-$3.57	N/A
Taysha Gene Therapies	$9.77M	175.30	-$109M	-$0.38	N/A

Kymera Therapeutics has a beta of 2.06, indicating that its stock price is 106% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

Taysha Gene Therapies has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Kymera Therapeutics currently has a consensus price target of $118.10, indicating a potential upside of 43.65%. Taysha Gene Therapies has a consensus price target of $11.64, indicating a potential upside of 95.24%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Taysha Gene Therapies beats Kymera Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Qiagen?

Qiagen (NYSE:QGEN) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

70.0% of Qiagen shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Qiagen had 5 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 9 mentions for Qiagen and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.69 beat Qiagen's score of 0.25 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a net margin of 19.16% compared to Taysha Gene Therapies' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Qiagen currently has a consensus price target of $46.38, indicating a potential upside of 40.53%. Taysha Gene Therapies has a consensus price target of $11.64, indicating a potential upside of 95.24%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Qiagen has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.25	$424.88M	$1.91	17.28
Taysha Gene Therapies	$9.77M	175.30	-$109M	-$0.38	N/A

Summary

Qiagen beats Taysha Gene Therapies on 9 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

TG Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Taysha Gene Therapies had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 4 mentions for Taysha Gene Therapies and 3 mentions for TG Therapeutics. Taysha Gene Therapies' average media sentiment score of 0.69 beat TG Therapeutics' score of 0.35 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 65.95% compared to Taysha Gene Therapies' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

TG Therapeutics currently has a consensus price target of $52.50, suggesting a potential upside of 32.91%. Taysha Gene Therapies has a consensus price target of $11.64, suggesting a potential upside of 95.24%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

TG Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.81	$447.18M	$2.86	13.81
Taysha Gene Therapies	$9.77M	175.30	-$109M	-$0.38	N/A

Summary

TG Therapeutics beats Taysha Gene Therapies on 9 of the 17 factors compared between the two stocks.

Get Taysha Gene Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSHA vs. The Competition

Export

Metric	Taysha Gene Therapies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.71B	$5.87B	$6.25B	$12.29B
Dividend Yield	N/A	0.68%	2.81%	5.30%
P/E Ratio	-15.68	8.49	20.40	25.26
Price / Sales	175.30	21.80	550.85	73.54
Price / Cash	N/A	8.55	27.48	37.27
Price / Book	6.62	4.05	9.74	6.71
Net Income	-$109M	$102.24M	$3.57B	$336.00M
7 Day Performance	-12.61%	-0.95%	-1.05%	-0.72%
1 Month Performance	-7.31%	-4.60%	-2.62%	-0.09%
1 Year Performance	120.74%	126.74%	33.52%	30.62%

Taysha Gene Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSHA Taysha Gene Therapies	2.9032 of 5 stars	$5.96 flat	$11.64 +95.2%	+120.7%	$1.71B	$9.77M	N/A	180	Gap Up
HHH Howard Hughes	3.4802 of 5 stars	$64.27 -2.3%	$85.00 +32.2%	-9.6%	$3.92B	$1.47B	31.51	608
PCVX Vaxcyte	2.8798 of 5 stars	$53.99 +1.8%	$86.00 +59.3%	+64.5%	$7.65B	N/A	N/A	160
KYMR Kymera Therapeutics	2.3412 of 5 stars	$84.10 -2.3%	$118.10 +40.4%	+171.8%	$7.08B	$39.21M	N/A	170
QGEN Qiagen	4.5514 of 5 stars	$32.63 -1.3%	$46.38 +42.1%	-26.5%	$6.81B	$2.09B	17.04	5,654	Dividend Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TSHA) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, PCVX, KYMR, QGEN, and TGTX

How does Taysha Gene Therapies compare to Howard Hughes?

Summary

How does Taysha Gene Therapies compare to Vaxcyte?

Summary

How does Taysha Gene Therapies compare to Kymera Therapeutics?

Summary

How does Taysha Gene Therapies compare to Qiagen?

Summary

How does Taysha Gene Therapies compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, PCVX, KYMR, QGEN, and TGTX

How does Taysha Gene Therapies compare to Howard Hughes?

Do insiders and institutionals believe in HHH or TSHA?

Does the media prefer HHH or TSHA?

Which has higher valuation and earnings, HHH or TSHA?

Do analysts prefer HHH or TSHA?

Is HHH or TSHA more profitable?

Which has more risk and volatility, HHH or TSHA?

Summary

How does Taysha Gene Therapies compare to Vaxcyte?

Do insiders and institutionals believe in PCVX or TSHA?

Does the media prefer PCVX or TSHA?

Which has higher valuation and earnings, PCVX or TSHA?

Which has more risk and volatility, PCVX or TSHA?

Is PCVX or TSHA more profitable?

Do analysts prefer PCVX or TSHA?

Summary

How does Taysha Gene Therapies compare to Kymera Therapeutics?

Do institutionals and insiders believe in KYMR or TSHA?

Does the media favor KYMR or TSHA?

Which has stronger earnings and valuation, KYMR or TSHA?

Which has more volatility & risk, KYMR or TSHA?

Is KYMR or TSHA more profitable?

Do analysts rate KYMR or TSHA?

Summary

How does Taysha Gene Therapies compare to Qiagen?

Which has more volatility & risk, QGEN or TSHA?

Do institutionals and insiders believe in QGEN or TSHA?

Does the media favor QGEN or TSHA?

Is QGEN or TSHA more profitable?

Do analysts rate QGEN or TSHA?

Which has stronger earnings and valuation, QGEN or TSHA?

Summary

How does Taysha Gene Therapies compare to TG Therapeutics?

Which has more volatility & risk, TGTX or TSHA?

Do insiders & institutionals hold more shares of TGTX or TSHA?

Does the media favor TGTX or TSHA?

Is TGTX or TSHA more profitable?

Do analysts recommend TGTX or TSHA?

Which has better valuation and earnings, TGTX or TSHA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools